Hematopoietic Stem Cell Variant Targeting for Clonal Hematopoiesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Somatic alterations in the blood, such as clonal hematopoiesis (CH), are associated with increased risks of hematological neoplasms, cardiovascular disease, and mortality, and existing treatments are inadequate in addressing these issues effectively.
Innovation Solution
Administering KNTC1 antagonists, RC3H1 agonists, YLPM1 agonists, or HLA-DRB5 agonists to subjects based on genetic variant analysis to treat, prevent, or reduce the development of CH and leukocyte telomere length (LTL) reductions, thereby modulating genetic and immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for clonal hematopoiesis, then general hematological conditions are addressed, but specific genetic variants and their associated risks are not effectively targeted
Solution Approach 1:
The patent applies local quality by tailoring treatment to specific genetic variants present in individual patients. Different KNTC1 antagonists, RC3H1 agonists, YLPM1 agonists, or HLA-DRB5 agonists are selected based on the patient's specific genetic profile, ensuring that the treatment is optimized for their unique molecular characteristics rather than using a one-size-fits-all approach.
Solution Approach 2:
The patent utilizes parameter changes by modifying treatment parameters (drug selection, dosage, combination) based on genetic test results. The treatment regimen is adjusted according to specific genetic variants detected through sequencing, allowing dynamic adaptation of therapeutic parameters to match the patient's genetic landscape and improve treatment effectiveness.
2Reliability
If genetic testing and personalized treatment protocols are implemented, then treatment effectiveness for specific variants improves, but device and process complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the treatment process into distinct modules: genetic testing, variant analysis, and targeted therapy selection. Each genetic variant (KNTC1, RC3H1, YLPM1, HLA-DRB5) has its own specific antagonist or agonist protocol, allowing the complex system to be managed through standardized, separable components rather than a monolithic approach.
Solution Approach 2:
The patent uses genetic test results as an intermediary that bridges the gap between diagnosis and treatment. The genetic analysis serves as a mediator that translates complex genomic data into actionable treatment recommendations, simplifying the decision-making process by providing clear variant-specific guidance for selecting appropriate therapies.
3Reliability
If early intervention based on genetic risk factors is implemented, then prevention of clonal hematopoiesis development improves, but time and resource investment increases
Solution Approach 1:
The patent applies preliminary action by performing genetic testing and identifying risk variants before clonal hematopoiesis fully develops or progresses to malignancy. By detecting genetic predispositions early (through KNTC1, RC3H1, YLPM1, or HLA-DRB5 variant analysis), the system enables proactive intervention with appropriate agonists or antagonists before the disease process advances, improving prevention effectiveness.
Solution Approach 2:
The patent implements feedback by using genetic test results to continuously guide treatment decisions and monitor response. The genetic profile serves as a baseline that informs initial treatment selection, and ongoing assessment of whether the chosen antagonist or agonist is effectively targeting the identified variant allows for real-time adjustments to maintain optimal prevention or treatment outcomes.
Data Source
AI summary
Methods of treating, preventing, or reducing somatic alterations of the blood of a subject with kinetochore associated 1 (KNTC1) antagonists, ring finger and CCCH-type domains 1 (RC3H1) agonists, YLP motif containing 1 (YLPM1) agonists, Major Histocompatibility Complex, Class II, and/or DR beta 5 (HLA-DRB5) agonists are provided herein. Methods of treating a subject with a therapeutic agent that treats, prevents, or reduces somatic alterations of the blood are also provided. Methods of identifying a subject having an increased risk of developing somatic alterations of the blood are also provided.